shot-button
Subscription Subscription
Home > Lifestyle News > Health And Fitness News > Article > Hydroxychloroquine medicine recommended to cure Covid 19 linked to 17000 deaths Study

Hydroxychloroquine, medicine recommended to cure Covid-19 linked to 17,000 deaths: Study

Updated on: 07 January,2024 08:55 AM IST  |  Washington
IANS |

During the Covid-19 pandemic, former US President Donald Trump urged Americans to take hydroxychloroquine (HCQ), an anti-malaria medicine that is also often used to cure rheumatoid arthritis and lupus

 Hydroxychloroquine, medicine recommended to cure Covid-19 linked to 17,000 deaths: Study

Image for representational purposes only. Photo Courtesy: iStock

Hydroxychloroquine (HCQ) recommended by physicians for curing Covid-19 has been linked to nearly 17,000 deaths, according to a new study as quoted by media reports.


A new study conducted by French researchers has found that nearly 17,000 people across six countries may have died after being prescribed hydroxychloroquine (HCQ) while hospitalised with illness from March to July 2020 during the first wave of Covid-19, Newsweek reported.


During the Covid-19 pandemic, former US President Donald Trump urged Americans to take hydroxychloroquine (HCQ), an anti-malaria medicine that is also often used to cure rheumatoid arthritis and lupus, claiming that he himself had been taking the "miracle" drug.


The research published in the February issue of Biomedicine & Pharmacotherapy shows that increase in the number of deaths was driven by side effects like heart arrhythmia and muscle weakness.

The countries studied were the US, Turkey, Belgium, France, Spain and Italy, Newsweek reported.

The US reported the highest numbers of deaths with 12,739, followed by Spain (1,895), Italy (1,822), Belgium (240), France (199) and Turkey (95).

The researchers said that the number of deaths could be much higher as their study only looked at only six countries between March and July 2020.

The scientists analysed various studies that tracked hospitalisations due to Covid-19 and exposure to the drug and risk related to it.

After the outbreak of coronavirus, scientists suggested that HCQ could be effective in treating the deadly virus, Newsweek reported.

On March 28, 2020, the Food and Drug Administration (FDA) approved the drug for an emergency use authorisation and started clinical trials.

However in June 2020, the FDA revoked the emergency use authorisation of the drug as several studies, including one by New England Journal of Medicine, found HCQ had no benefit on Covid and led to significant surge in the risk of death. The FDA revoked the emergency use authorisation on June 15, 2020.

While one scientist called the HCQ a "magic bullet" against coronavirus, Trump highlighted the "miracle" recovery made by a Covid-infected woman after using the drug, Newsweek reported.

"The nice part is, it's been around for a long time...if things don't go as planned, it's not going to kill anybody," the ex-US President Trump said during a Covid Taskforce briefing.

In a tweet on March 21, 2020, he added that "FDA has moved mountains" and that the drug would be put to use "immediately" as an antidote to curb Covid transmission.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!

Register for FREE
to continue reading !

This is not a paywall.
However, your registration helps us understand your preferences better and enables us to provide insightful and credible journalism for all our readers.

Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK